A group of investors have won a dispute against a Newcastle-based company over a foreclosure on a mortgage in relation to a Gold Coast which did not proceed.
Former senior barrister Norman O’Bryan has pleaded not guilty to two criminal charges in connection with his role as counsel for the Banksia Securities class action.
Former barrister Norman O’Bryan has lost his bid to suppress reporting on the hearing where he was committed to stand trial for criminal offences related to his role in the Banksia class action, with a magistrate finding the orders would be “futile”.
A judge has struck down controversial new anti-protest laws in New South Wales which gave police powers to shut down protests “in or near a place of worship”, finding they were contrary to the freedom of political communication.
Having lost a challenge to privatisation agreements by NSW Ports, the competition regulator wants to intervene in a High Court appeal by Mayfield Developments, which failed in its own case against the port authority.
The receiver for Brazilian mining company Atlantic Nickel has prevailed in a second attempt to stay a case by Mining Services International, which brought a $1 billion claim over a terminated sale of a mine in Santa Rica.
AUSTRAC would get new powers to restrict or ban certain high-risk products, services or delivery channels, such as crypto ATMs, under legislation being proposed by home affairs minister.
The Victorian Supreme Court has granted cosmetic surgeon Daniel Lanzer an extension to provide discovery in a class action against him and his clinic after hearing he was facing medical issues.
Blooms the Chemist can’t overturn a decision from the Pharmacy Council of NSW blocking the registration of a chemist, with a judge finding there was no evidence Blooms would not have a financial interest in the business.
Mayne Pharma has won a dispute with US drug maker Cosette over the termination of a $672 million merger agreement, with a judge finding Mayne did not breach its continuous disclosure obligations by failing to disclose a letter from the US FDA sooner.